A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

This study has been withdrawn prior to enrollment.

(Cost prohibitive and company withdrew support.)

Sponsor:

Collaborator:

Sunovion

Information provided by (Responsible Party):

University of Chicago

ClinicalTrials.gov Identifier:

NCT00793858

First received: November 14, 2008

Last updated: June 6, 2013

Last verified: June 2013

History of Changes

Purpose

The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose

Condition	Intervention	Phase
Allergic Rhinitis	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single Blind (Subject) Primary Purpose: Basic Science
Official Title:	A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).

Resource links provided by NLM:

Drug Information available for: Ciclesonide

U.S. FDA Resources

Further study details as provided by University of Chicago:

Primary Outcome Measures:

levels of ciclesonide in biopsy tissue [ Time Frame: 2 hours post study drug administration ] [ Designated as safety issue: No ]


Enrollment:	0
Study Start Date:	February 2009
Estimated Primary Completion Date:	September 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 placebo in left nostril, isotonic ciclesonide in right	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril
Active Comparator: 2 hypotonic ciclesonide in left nostril, placebo in right	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril
Active Comparator: 3 hypotonic ciclesonide in right and left nostrils	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril
Active Comparator: 4 isotonic ciclesonide in both right and left nostrils	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril
Placebo Comparator: 6 placebo in both right and left nostrils	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril
Active Comparator: 5 isotonic ciclesonide in left nostril and hypotonic ciclesonide in right	Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide 200mcg/nostril

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males and females 18 years of age or older.
History of perennial allergic rhinitis for at least 1 year prior to screening.
Positive skin test to perennial allergen.

Exclusion Criteria:

Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
Pregnant or lactating women.
Upper respiratory infection within 14 days of study start.
Active asthma requiring treatment with inhaled or systemic steroids.
Use of any form of nasal spray during the previous month.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00793858

Locations


United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States, 60637

Sponsors and Collaborators

University of Chicago

Sunovion

More Information


Responsible Party:	University of Chicago
ClinicalTrials.gov Identifier:	NCT00793858 History of Changes
Other Study ID Numbers:	16651A (SEP 1)
Study First Received:	November 14, 2008
Last Updated:	June 6, 2013
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:


Rhinitis Rhinitis, Allergic Nose Diseases Respiratory Tract Diseases Respiratory Tract Infections Otorhinolaryngologic Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate	Hypersensitivity Immune System Diseases Ciclesonide Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 27, 2016

To Top